5:00 pm
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects that develop or validate emerging technologies that contribute to targeting, probing, or...
5:00 pm
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects focused on the inception and early-stage development of innovative molecular and cellular...
5:00 pm
The NIH’s National Cancer Institute will fund up to $325,000 per year for projects developing new technical capabilities for cancer research and clinical oncology. This funding opportunity lines up with the Blue Ribbon Panel (BRP) of the...
5:00 pm
The National Cancer Institute will award $400,000 per year for up to five years for projects that develop state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue...
5:00 pm
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects that develop or validate emerging technologies that contribute to targeting, probing, or...
5:00 pm
The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects focused on the inception and early-stage development of innovative molecular and cellular...
5:00 pm
The National Cancer Institute will award $400,000 per year for up to five years for projects that develop state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue...
Apr
26
Wed
DEADLINE: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent
Apr 26 @ 5:00 pm
DEADLINE: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent

The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects that develop or validate emerging technologies that contribute to targeting, probing, or assessing molecular and cellular features of cancer biology. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.

Learn more and submit your Letter of Intent.

Source: National Cancer Institute

DEADLINE: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent
Apr 26 @ 5:00 pm
DEADLINE: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent

The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects focused on the inception and early-stage development of innovative molecular and cellular analysis technologies. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.

Learn more and submit your Letter of Intent.

Source: National Cancer Institute

May
10
Wed
DEADLINE: Integration and Validation of Emerging Technologies to Accelerate Cancer Research Application
May 10 @ 5:00 pm
DEADLINE: Integration and Validation of Emerging Technologies to Accelerate Cancer Research Application

The NIH’s National Cancer Institute will fund up to $325,000 per year for projects developing new technical capabilities for cancer research and clinical oncology. This funding opportunity lines up with the Blue Ribbon Panel (BRP) of the Beau Biden Cancer MoonshotSM Initiative goals. Priority areas include a focus on experimental and analytical capabilities addressing cancer development; technologies advancing precise cancer diagnoses; new predictive models; and new technologies/approaches to improve biospecimen and data quality.

Learn more and submit your application here.

Source: NIH

Jun
5
Mon
DEADLINE: Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research Application
Jun 5 @ 5:00 pm
DEADLINE: Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research Application

The National Cancer Institute will award $400,000 per year for up to five years for projects that develop state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology. The projects supported by this FOA will establish and collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program.

Learn more and submit your application here.

Source: NIH

Aug
26
Sat
DEADLINE: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent
Aug 26 @ 5:00 pm
DEADLINE: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent

The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects that develop or validate emerging technologies that contribute to targeting, probing, or assessing molecular and cellular features of cancer biology. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.

Learn more and submit your Letter of Intent.

Source: National Cancer Institute

DEADLINE: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent
Aug 26 @ 5:00 pm
DEADLINE: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research Letter of Intent

The NIH’s National Cancer Institute (the NIH is the parent organization of the ITM) will fund $4 million to approximately 10 exploratory projects focused on the inception and early-stage development of innovative molecular and cellular analysis technologies. Projects should show potential to improve cancer biology research, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.

Learn more and submit your Letter of Intent.

Source: National Cancer Institute

Oct
5
Thu
DEADLINE: Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research Application
Oct 5 @ 5:00 pm
DEADLINE: Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research Application

The National Cancer Institute will award $400,000 per year for up to five years for projects that develop state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology. The projects supported by this FOA will establish and collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program.

Learn more and submit your application here.

Source: NIH